Form 4: Inovio Pharmaceuticals CEO Jacqueline Shea Reports Stock Transactions
SEC Form 4
CEO Jacqueline Shea reports the vesting of restricted stock units and subsequent tax withholding by Inovio Pharmaceuticals.
Summary
- On May 10, 2025, Jacqueline Shea, CEO of Inovio Pharmaceuticals, had 5,500 restricted stock units vest, which were then converted into common stock.
- The company withheld 2,392 shares to cover Shea's tax obligations related to the vesting of these units at a price of $1.8 per share.
- Following these transactions, Shea directly owns 49,658 shares of Inovio Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions related to executive compensation; it doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Key Dates
| Date | Description |
|---|---|
| 05/10/2023 | 5,500 restricted stock units vested. |
| 05/10/2024 | 5,500 restricted stock units vested. |
| 05/10/2025 | 5,500 restricted stock units vested; tax withholding of 2,392 shares. |
| 05/12/2025 | Date of Form 4 signature. |
Keywords
Inovio Pharmaceuticals, Jacqueline Shea, restricted stock units, Form 4, beneficial ownership, stock transactions, INO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.